137 results on '"Davila, Marco L"'
Search Results
2. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy
3. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
4. Large Scale Ex Vivo Expansion of γδ T cells Using Artificial Antigen-presenting Cells
5. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
6. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma
7. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis
8. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma
9. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL
10. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
11. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease
12. Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
13. Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
14. Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
15. Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
16. Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
17. Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)
18. Biphasic Neutrophil Recovery after CD19 CART in R/R LBCL Is Associated with Superior PFS/OS, Robust CAR T-Cell Expansion in Relation to Baseline Tumor Volume, and a Decrease of Systemic Inflammation over Time
19. Baseline Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
20. Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis
21. Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
22. Chimeric Antigen Receptor Design Today and Tomorrow.
23. Interventions and outcomes of adult patients with B-ALL progressing after CD19 chimeric antigen receptor T-cell therapy
24. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma
25. Regulatory challenges and considerations for the clinical application of CAR T cell therapy
26. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma
27. JAK2/mTOR Inhibition Fails to Prevent Acute GVHD Despite Reduced Th1/Th17 cells: Final Phase II Trial Results
28. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
29. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation
30. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma
31. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation
32. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
33. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma
34. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
35. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma
36. Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells
37. Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/ Refractory Multiple Myeloma (RRMM)
38. Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel
39. Disruption of a self-amplifying catecholamine loop reduces cytokine release syndrome
40. Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
41. A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia
42. A Novel IL2Rα-/- Model for CAR-T Toxicity in Acute Lymphoblastic Leukemia Recapitulates Cytokine Release Syndrome and Neutropenia
43. Bispecific CD33/CD123 Targeted Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia
44. The Latest Advances in CAR T-Cell Therapy for Refractory and Relapsed Lymphomas and Leukemias.
45. Concise Review: Emerging Principles from the Clinical Application of Chimeric Antigen Receptor T Cell Therapies for B Cell Malignancies
46. CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date.
47. Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
48. At The Bedside: Clinical review of chimeric antigen receptor (CAR) T cell therapy for B cell malignancies
49. Measurable Residual Disease Outcompetes Cytogenetics in Predicting Leukemia Free Survival Following Allogeneic Stem Cell Transplantation Outcomes in Adults with Acute Lymphoblastic Leukemia
50. Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.